TG Therapeutics Inc. has announced the completion of enrollment in the randomized cohort of its Phase 3 ENHANCE trial. The study is evaluating a new, consolidated dosing schedule for intravenous BRIUMVI® (ublituximab-xiiy) in individuals with relapsing forms of multiple sclerosis (RMS). The trial is designed to assess whether combining the Day 1 and Day 15 infusions into a single Day 1 infusion maintains drug exposure levels comparable to the existing approved regimen. The primary endpoint is non-inferior exposure with respect to area under the curve (AUC) at week 16. Results from the study have not yet been presented, and if positive, TG Therapeutics anticipates that the new dosing regimen could be available for launch in 2027.